サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1754835

網膜色素変性症の世界市場：2034年までの機会と戦略

Retinitis Pigmentosa Global Market Opportunities And Strategies To 2034

出版日
ページ情報
英文 337 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.80円
網膜色素変性症の世界市場：2034年までの機会と戦略
出版日: 2025年06月16日
発行: The Business Research Company
ページ情報: 英文 337 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の網膜色素変性症市場は2019年に88億895万米ドルと評価され、2024年までCAGR5.00％以上で成長しました。

個別化医療に対する需要の高まり

個別化医療に対する需要の高まりは、歴史的な期間における網膜色素変性症市場の拡大を促進する上で重要な役割を果たしています。個別化医療は、遺伝的体質、ライフスタイル、環境に基づいて、個々の患者に合わせた治療やヘルスケア決定を行うものです。個別化医療に対する需要の急増は、ゲノミクスの進歩、慢性疾患の増加、治療結果の改善、規制当局のサポート、ヘルスケアにおけるAIとビッグデータの利用の増加によってもたらされます。網膜色素変性症の場合、個別化医療には遺伝子治療、遺伝子検査、Luxturna、幹細胞治療、網膜インプラントなどの精密治療が含まれ、これらはすべて特定の遺伝子変異を標的とし、疾患の進行を遅らせることを目的としています。例えば、科学者、患者、医療提供者を代表する米国の組織である個別化医療連合（Personalized Medicine Coalition）によると、2024年2月、米国食品医薬品局（FDA）は、2023年に希少疾患患者のために16の新たな個別化治療を承認し、2022年の6承認から増加しました。その結果、個別化医療に対する需要の高まりが網膜色素変性症市場の成長を大きく後押ししています。

目次

第1章 エグゼクティブサマリー

  • 網膜色素変性症-市場の魅力とマクロ経済情勢

第2章 目次

第3章 表一覧

第4章 図一覧

第5章 レポート構成

第6章 市場の特徴

  • 一般的な市場の定義
  • 概要
  • 網膜色素変性症市場定義とセグメンテーション
  • 市場セグメンテーション：タイプ別
    • 常染色体劣性
    • 常染色体優性
    • X連鎖
  • 市場セグメンテーション：治療別
    • ビタミンA
    • ドコサヘキサエン酸（DHA）
    • カルシウムチャネル遮断薬
    • 遺伝子治療
    • 網膜義眼
    • その他の治療
  • 市場セグメンテーション：診断別
    • 網膜電図
    • 視野検査
    • 遺伝子検査
    • その他の診断
  • 市場セグメンテーション：流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • その他の流通チャネル
  • 市場セグメンテーション：エンドユーザー別
    • 病院
    • 専門クリニック
    • 在宅ケア
    • その他のエンドユーザー

第7章 主要な市場動向

  • 網膜色素変性症治療の進歩を推進する戦略的連携
  • 規制当局の承認が網膜色素変性症の遺伝子治療の進歩を促進
  • 臨床試験を通じて網膜色素変性症の治療を進歩させる
  • X連鎖性網膜色素変性症に対する遺伝子治療の進歩

第8章 全網膜色素変性症

  • 世界の網膜色素変性症のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
    • 政治的
    • 経済
    • 社会
    • 技術的
    • 環境
    • 法律上
  • エンドユーザー分析（B2B）
    • 病院
    • 専門クリニック
    • ホームケアサービス
    • その他のエンドユーザー
  • 世界の網膜色素変性症市場：成長率分析
  • 市場成長実績, 2019-2024
    • 市場促進要因2019年～2024年
    • 市場抑制要因2019年-2024年
  • 市場成長予測, 2024-2029, 2034F
    • 市場促進要因2024年～2029年
    • 市場抑制要因2024年～2029年
  • 成長予測の貢献要因
    • 量的成長の貢献者
    • 促進要因
    • 抑制要因
  • 世界の網膜色素変性症の総アドレス可能市場（TAM）

第9章 世界の網膜色素変性症市場：セグメンテーション

  • 世界の網膜色素変性症市場：タイプ別、実績と予測, 2019-2024, 2029F, 2034F
  • 世界の網膜色素変性症市場：治療別、実績と予測, 2019-2024, 2029F, 2034F
  • 世界の網膜色素変性症市場：診断別、実績と予測, 2019-2024, 2029F, 2034F
  • 世界の網膜色素変性症市場：流通チャネル別、実績と予測, 2019-2024, 2029F, 2034F
  • 世界の網膜色素変性症市場：エンドユーザー別、実績と予測, 2019-2024, 2029F, 2034F
  • 世界の網膜色素変性症市場、常染色体劣性のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2029F, 2034F
  • 世界の網膜色素変性症市場、常染色体優性のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2029F, 2034F
  • 世界の網膜色素変性症市場、X連鎖のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2029F, 2034F

第10章 網膜色素変性症市場：地域・国別分析

  • 世界の網膜色素変性症市場：地域別、実績と予測, 2019-2024, 2029F, 2034F
  • 世界の網膜色素変性症市場：国別、実績と予測, 2019-2024, 2029F, 2034F

第11章 アジア太平洋市場

第12章 西欧市場

第13章 東欧市場

第14章 北米市場

第15章 南米市場

第16章 中東市場

第17章 アフリカ市場

第18章 競合情勢と企業プロファイル

  • 企業プロファイル
  • Johnson & Johnson
  • Novartis AG
  • Astellas Pharma Inc
  • Biogen Inc
  • Sun Pharmaceutical Industries Ltd

第19章 その他の大手企業と革新的企業

  • Oxford Biomedical Inc
  • Spark Therapeutics Inc
  • MeiraGTx Ltd
  • Editas Medicine Inc
  • 4D Molecular Therapeutics Inc
  • PYC Therapeutics Ltd
  • AbbVie Inc
  • Beacon Therapeutics Inc
  • Nanoscope Therapeutics Inc
  • Nacuity Pharmaceuticals Inc
  • Alia Therapeutics Srl
  • Ray Therapeutics Inc
  • jCyte Inc
  • ProQR Therapeutics NV
  • Acucela Inc

第20章 競合ベンチマーキング

第21章 競合ダッシュボード

第22章 主要な合併と買収

  • Ocuphire Pharma Acquired Opus Genetics Inc.
  • Astellas Pharma Inc. Acquired Iveric Bio Inc.
  • Syncona Acquired Applied Genetic Technologies Corporation

第23章 最近の動向網膜色素変性症市場

第24章 機会と戦略

  • 世界の網膜色素変性症市場2029：新たな機会を提供する国
  • 世界の網膜色素変性症市場2029：新たな機会を提供するセグメント
  • 世界の網膜色素変性症市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第25章 網膜色素変性症市場：結論と提言

  • 結論
  • 提言
    • 製品
    • 場所
    • 価格
    • プロモーション
    • 人々

第26章 付録

目次
Product Code: o&s1644

Retinitis Pigmentosa (RP) is a group of rare, inherited eye disorders that cause progressive degeneration of the retina, leading to vision loss. The condition primarily affects the retina's photoreceptor cells (rods and cones), which are responsible for detecting light and color. It is caused by mutations in certain genes that affect the function and survival of photoreceptor cells.

The retinitis pigmentosa market consists of sales, by entities (organizations, sole traders and partnerships), of retinitis pigmentosa is a group of inherited disorders causing progressive degeneration of the retina, leading to vision loss. It primarily affects photoreceptor cells (rods and cones), resulting in symptoms such as night blindness and tunnel vision. Over time, RP can lead to significant visual impairment and blindness.

The global retinitis pigmentosa market was valued at $8,808.95 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 5.00%.

Rising Demand For Personalized Medicine

The growing demand for personalized medicine has played a key role in driving the expansion of the retinitis pigmentosa market during the historical period. Personalized medicine tailors' treatments and healthcare decisions to individual patients based on their genetic makeup, lifestyle and environment. The surge in demand for personalized medicine is driven by advancements in genomics, a rise in chronic diseases, improved treatment outcomes, regulatory support and the increasing use of AI and big data in healthcare. For retinitis pigmentosa, personalized medicine includes gene therapy, genetic testing and precision treatments such as Luxturna, stem cell therapy and retinal implants, all aimed at targeting specific genetic mutations and slowing disease progression. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022. As a result, the rising demand for personalized medicine has significantly fueled the growth of the retinitis pigmentosa market.

Strategic Collaborations Driving Advancements In Retinitis Pigmentosa Treatment

Major companies in the retinitis pigmentosa market are focusing on adopting strategic collaborations to accelerate research, enhance gene therapy development and expand treatment access. Strategic collaborations refer to partnerships between biotech firms, pharmaceutical companies and research institutions to accelerate gene therapy development, optimize clinical trials and enhance treatment accessibility through data-driven insights and regulatory support. For instance, in February 2025, Verana Health, a US-based digital health company, partnered with Nanoscope Therapeutics Inc., a US-based biotechnology company, to accelerate research into retinitis pigmentosa (RP), a progressive retinal disease that can lead to blindness. By utilizing Verana's extensive Qdata Retinitis Pigmentosa dataset, which includes insights from over 70,000 de-identified patients, the collaboration aims to enhance the development of Nanoscope's optogenetic gene therapy, MCO-010. This partnership emphasizes the role of real-world data in improving clinical trial strategies and patient outcomes, ultimately paving the way for more effective treatments for individuals affected by RP.

The global retinitis pigmentosa market is fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 6.80% of the total market in 2023.

Retinitis Pigmentosa Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global retinitis pigmentosa market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for retinitis pigmentosa? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The retinitis pigmentosa market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider retinitis pigmentosa market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by treatment, by diagnosis, by distribution channel and by end-users.
  • Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Growth Analysis And Strategic Analysis Framework - Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
  • Global Market Size And Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by treatment, by diagnosis, by distribution channel and by end-users in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
  • Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard- Briefs on competitive dashboard of major players.
  • Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Recent Developments - Information on recent developments in the market covered in the report.
  • Market Opportunities And Strategies Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to retinitis pigmentosa be followed in those markets.
  • Conclusions And Recommendations This section includes recommendations for retinitis pigmentosa market providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Type: Autosomal Recessive; Autosomal Dominant; X-Linked
  • 2) By Treatment: Vitamin A; Docosahexaenoic Acid (DHA); Calcium Channel Blockers; Gene Therapy; Retinal Eye Prosthetics; Other Treatments
  • 3) By Diagnosis: Electroretinogram; Visual Field Testing; Genetic Testing; Other Diagnostic Methods
  • 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
  • Companies Mentioned: Johnson & Johnson; Novartis AG; Astellas Pharma Inc.; Biogen Inc.; Sun Pharmaceutical Industries Ltd.
  • Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; retinitis pigmentosa indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Retinitis Pigmentosa - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Retinitis Pigmentosa Market Definition And Segmentations
  • 6.4 Market Segmentation By Type
    • 6.4.1 Autosomal Recessive
    • 6.4.2 Autosomal Dominant
    • 6.4.3 X-Linked
  • 6.5 Market Segmentation By Treatment
    • 6.5.1 Vitamin A
    • 6.5.2 Docosahexaenoic Acid (DHA)
    • 6.5.3 Calcium Channel Blockers
    • 6.5.4 Gene Therapy
    • 6.5.5 Retinal Eye Prosthetics
    • 6.5.6 Other Treatments
  • 6.6 Market Segmentation By Diagnosis
    • 6.6.1 Electroretinogram
    • 6.6.2 Visual Field Testing
    • 6.6.3 Genetic Testing
    • 6.6.4 Other Diagnosis
  • 6.7 Market Segmentation By Distribution Channel
    • 6.7.1 Hospital Pharmacy
    • 6.7.2 Retail Pharmacy
    • 6.7.3 Online Pharmacy
    • 6.7.4 Other Distribution Channels
  • 6.8 Market Segmentation By End-Users
    • 6.8.1 Hospitals
    • 6.8.2 Specialty Clinics
    • 6.8.3 Homecare
    • 6.8.4 Other End-Users

7 Major Market Trends

  • 7.1 Strategic Collaborations Driving Advancements In Retinitis Pigmentosa Treatment
  • 7.2 Regulatory Approvals Drive Advancements In Retinitis Pigmentosa Gene Therapies
  • 7.3 Advancing Retinitis Pigmentosa Treatment Through Clinical Trials
  • 7.4 Advancing Gene Therapy For X-Linked Retinitis Pigmentosa

8 Global Retinitis Pigmentosa

  • 8.1 Global Retinitis Pigmentosa PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
    • 8.1.1 Political
    • 8.1.2 Economic
    • 8.1.3 Social
    • 8.1.4 Technological
    • 8.1.5 Environmental
    • 8.1.6 Legal
  • 8.2 Analysis Of End Users (B2B)
    • 8.2.1 Hospital
    • 8.2.2 Specialty Clinics
    • 8.2.3 Homecare Services
    • 8.2.4 Other End-Users
  • 8.3 Global Retinitis Pigmentosa Market Growth Rate Analysis
  • 8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
    • 8.4.1 Market Drivers 2019 - 2024
    • 8.4.2 Market Restraints 2019 - 2024
  • 8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
    • 8.5.1 Market Drivers 2024 - 2029
    • 8.5.2 Market Restraints 2024 - 2029
  • 8.6 Forecast Growth Contributors/Factors
    • 8.6.1 Quantitative Growth Contributors
    • 8.6.2 Drivers
    • 8.6.3 Restraints
  • 8.7 Global Retinitis Pigmentosa Total Addressable Market (TAM)

9 Global Retinitis Pigmentosa Market Segmentation

  • 9.1 Global Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.2 Global Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.3 Global Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.4 Global Retinitis Pigmentosa Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.5 Global Retinitis Pigmentosa Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.6 Global Retinitis Pigmentosa Market, Sub-Segmentation Of Autosomal Recessive, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.7 Global Retinitis Pigmentosa Market, Sub-Segmentation Of Autosomal Dominant, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.8 Global Retinitis Pigmentosa Market, Sub-Segmentation Of X-Linked, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Retinitis Pigmentosa Market, Regional and Country Analysis

  • 10.1 Global Retinitis Pigmentosa Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.2 Global Retinitis Pigmentosa Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

  • 11.1 Summary
  • 11.2 Market Overview
    • 11.2.1 Region Information
    • 11.2.2 Market Information
    • 11.2.3 Background Information
    • 11.2.4 Government Initiatives
    • 11.2.5 Regulations
    • 11.2.6 Regulatory Bodies
    • 11.2.7 Major Associations
    • 11.2.8 Taxes Levied
    • 11.2.9 Corporate Tax Structure
    • 11.2.10 Investments
    • 11.2.11 Major Companies
  • 11.3 Asia-Pacific Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.4 Asia-Pacific Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.5 Asia-Pacific Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.6 Asia-Pacific Retinitis Pigmentosa Market: Country Analysis
  • 11.7 China Market
  • 11.8 Summary
  • 11.9 Market Overview
    • 11.9.1 Country Information
    • 11.9.2 Market Information
    • 11.9.3 Background Information
    • 11.9.4 Government Initiatives
    • 11.9.5 Regulations
    • 11.9.6 Regulatory Bodies
    • 11.9.7 Major Associations
    • 11.9.8 Taxes Levied
    • 11.9.9 Corporate Tax Structure
    • 11.9.10 Investments
    • 11.9.11 Major Companies
  • 11.10 China Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.11 China Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.12 China Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.13 India Market
  • 11.14 India Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.15 India Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.16 India Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.17 Japan Market
  • 11.18 Summary
  • 11.19 Market Overview
    • 11.19.1 Country Information
    • 11.19.2 Market Information
    • 11.19.3 Background Information
    • 11.19.4 Government Initiatives
    • 11.19.5 Regulations
    • 11.19.6 Regulatory Bodies
    • 11.19.7 Major Associations
    • 11.19.8 Taxes Levied
    • 11.19.9 Corporate Tax Structure
    • 11.19.10 Investments
    • 11.19.11 Major Companies
  • 11.20 Japan Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.21 Japan Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.22 Japan Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.23 South Korea Market
  • 11.24 Summary
  • 11.25 Market Overview
    • 11.25.1 Country Information
    • 11.25.2 Market Information
    • 11.25.3 Background Information
    • 11.25.4 Regulations
    • 11.25.5 Regulatory Bodies
    • 11.25.6 Major Associations
    • 11.25.7 Taxes Levied
    • 11.25.8 Corporate Tax Structure
    • 11.25.9 Investments
    • 11.25.10 Major Companies
  • 11.26 South Korea Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.27 South Korea Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.28 South Korea Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.29 Australia Market
  • 11.30 Australia Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.31 Australia Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.32 Australia Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.33 Indonesia Market
  • 11.34 Indonesia Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.35 Indonesia Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.36 Indonesia Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

  • 12.1 Summary
  • 12.2 Market Overview
    • 12.2.1 Region Information
    • 12.2.2 Market Information
    • 12.2.3 Background Information
    • 12.2.4 Government Initiatives
    • 12.2.5 Regulations
    • 12.2.6 Regulatory Bodies
    • 12.2.7 Major Associations
    • 12.2.8 Taxes Levied
    • 12.2.9 Corporate tax structure
    • 12.2.10 Investments
    • 12.2.11 Major Companies
  • 12.3 Western Europe Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.4 Western Europe Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.5 Western Europe Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.6 Western Europe Retinitis Pigmentosa Market: Country Analysis
  • 12.7 UK Market
  • 12.8 UK Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.9 UK Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.10 UK Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.11 Germany Market
  • 12.12 Germany Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.13 Germany Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.14 Germany Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.15 France Market
  • 12.16 France Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.17 France Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.18 France Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.19 Italy Market
  • 12.20 Italy Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.21 Italy Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.22 Italy Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.23 Spain Market
  • 12.24 Spain Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.25 Spain Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.26 Spain Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

  • 13.1 Summary
  • 13.2 Market Overview
    • 13.2.1 Region Information
    • 13.2.2 Market Information
    • 13.2.3 Background Information
    • 13.2.4 Government Initiatives
    • 13.2.5 Regulations
    • 13.2.6 Regulatory Bodies
    • 13.2.7 Major Associations
    • 13.2.8 Taxes Levied
    • 13.2.9 Corporate Tax Structure
    • 13.2.10 Investments
    • 13.2.11 Major companies
  • 13.3 Eastern Europe Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.4 Eastern Europe Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.5 Eastern Europe Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.6 Russia Market
  • 13.7 Russia Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.8 Russia Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.9 Russia Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

  • 14.1 Summary
  • 14.2 Market Overview
    • 14.2.1 Region Information
    • 14.2.2 Market Information
    • 14.2.3 Background Information
    • 14.2.4 Government Initiatives
    • 14.2.5 Regulations
    • 14.2.6 Regulatory Bodies
    • 14.2.7 Major Associations
    • 14.2.8 Taxes Levied
    • 14.2.9 Corporate Tax Structure
    • 14.2.10 Investments
    • 14.2.11 Major Companies
  • 14.3 North America Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.4 North America Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.5 North America Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.6 North America Retinitis Pigmentosa Market: Country Analysis
  • 14.7 USA Market
  • 14.8 Summary
  • 14.9 Market Overview
    • 14.9.1 Country Information
    • 14.9.2 Market Information
    • 14.9.3 Background Information
    • 14.9.4 Government Initiatives
    • 14.9.5 Regulations
    • 14.9.6 Regulatory Bodies
    • 14.9.7 Major Associations
    • 14.9.8 Taxes Levied
    • 14.9.9 Corporate Tax Structure
    • 14.9.10 Investments
    • 14.9.11 Major Companies
  • 14.10 USA Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.11 USA Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.12 USA Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.13 Canada Market
  • 14.14 Summary
  • 14.15 Market Overview
    • 14.15.1 Country Information
    • 14.15.2 Market Information
    • 14.15.3 Background Information
    • 14.15.4 Government Initiatives
    • 14.15.5 Regulations
    • 14.15.6 Regulatory Bodies
    • 14.15.7 Major Associations
    • 14.15.8 Taxes Levied
    • 14.15.9 Corporate Tax Structure
    • 14.15.10 Investments
    • 14.15.11 Major Companies
  • 14.16 Canada Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.17 Canada Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.18 Canada Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

  • 15.1 Summary
  • 15.2 Market Overview
    • 15.2.1 Region Information
    • 15.2.2 Market Information
    • 15.2.3 Background Information
    • 15.2.4 Government Initiatives
    • 15.2.5 Regulations
    • 15.2.6 Regulatory Bodies
    • 15.2.7 Major Associations
    • 15.2.8 Taxes Levied
    • 15.2.9 Corporate Tax Structure
    • 15.2.10 Major Companies
  • 15.3 South America Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.4 South America Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.5 South America Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.6 Brazil Market
  • 15.7 Brazil Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.8 Brazil Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.9 Brazil Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

  • 16.1 Summary
  • 16.2 Market Overview
    • 16.2.1 Region Information
    • 16.2.2 Market Information
    • 16.2.3 Background Information
    • 16.2.4 Government Initiatives
    • 16.2.5 Regulations
    • 16.2.6 Regulatory Bodies
    • 16.2.7 Major Associations
    • 16.2.8 Taxes Levied
    • 16.2.9 Corporate Tax Structure
    • 16.2.10 Major Companies
  • 16.3 Middle East Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.4 Middle East Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.5 Middle East Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

  • 17.1 Summary
  • 17.2 Market Overview
    • 17.2.1 Region Information
    • 17.2.2 Market Information
    • 17.2.3 Background Information
    • 17.2.4 Government Initiatives
    • 17.2.5 Regulations
    • 17.2.6 Regulatory Bodies
    • 17.2.7 Major Associations
    • 17.2.8 Taxes Levied
    • 17.2.9 Corporate Tax Structure
    • 17.2.10 Major Companies
  • 17.3 Africa Retinitis Pigmentosa Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.4 Africa Retinitis Pigmentosa Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.5 Africa Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

  • 18.1 Company Profiles
  • 18.2 Johnson & Johnson
    • 18.2.1 Company Overview
    • 18.2.2 Products And Services
    • 18.2.3 Business Strategy
    • 18.2.4 Financial Overview
  • 18.3 Novartis AG
    • 18.3.1 Company Overview
    • 18.3.2 Products And Services
    • 18.3.3 Business Strategy
    • 18.3.4 Financial Overview
  • 18.4 Astellas Pharma Inc
    • 18.4.1 Company Overview
    • 18.4.2 Products And Services
    • 18.4.3 Business Strategy
    • 18.4.4 Financial Overview
  • 18.5 Biogen Inc
    • 18.5.1 Company Overview
    • 18.5.2 Products And Services
    • 18.5.3 Business Strategy
    • 18.5.4 Financial Overview
  • 18.6 Sun Pharmaceutical Industries Ltd
    • 18.6.1 Company Overview
    • 18.6.2 Products And Services
    • 18.6.3 Business Strategy
    • 18.6.4 Financial Overview

19 Other Major And Innovative Companies

  • 19.1 Oxford Biomedical Inc
    • 19.1.1 Company Overview
    • 19.1.2 Products And Services
  • 19.2 Spark Therapeutics Inc
    • 19.2.1 Company Overview
    • 19.2.2 Products and Services
  • 19.3 MeiraGTx Ltd
    • 19.3.1 Company Overview
    • 19.3.2 Products and Services
  • 19.4 Editas Medicine Inc
    • 19.4.1 Company Overview
    • 19.4.2 Products And Services
  • 19.5 4D Molecular Therapeutics Inc
    • 19.5.1 Company Overview
    • 19.5.2 Products and Services
  • 19.6 PYC Therapeutics Ltd
    • 19.6.1 Company Overview
    • 19.6.2 Products and Services
  • 19.7 AbbVie Inc
    • 19.7.1 Company Overview
    • 19.7.2 Products and Services
  • 19.8 Beacon Therapeutics Inc
    • 19.8.1 Company Overview
    • 19.8.2 Products and Services
  • 19.9 Nanoscope Therapeutics Inc
    • 19.9.1 Company Overview
    • 19.9.2 Products and Services
  • 19.10 Nacuity Pharmaceuticals Inc
    • 19.10.1 Company Overview
    • 19.10.2 Products and Services
  • 19.11 Alia Therapeutics Srl
    • 19.11.1 Company Overview
    • 19.11.2 Products and Services
  • 19.12 Ray Therapeutics Inc
    • 19.12.1 Company Overview
    • 19.12.2 Products and Services
  • 19.13 jCyte Inc
    • 19.13.1 Company Overview
    • 19.13.2 Products and Services
  • 19.14 ProQR Therapeutics NV
    • 19.14.1 Company Overview
    • 19.14.2 Products and Services
  • 19.15 Acucela Inc
    • 19.15.1 Company Overview
    • 19.15.2 Products and Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

  • 22.1 Ocuphire Pharma Acquired Opus Genetics Inc.
  • 22.2 Astellas Pharma Inc. Acquired Iveric Bio Inc.
  • 22.3 Syncona Acquired Applied Genetic Technologies Corporation

23 Recent Developments In The Retinitis Pigmentosa Market

  • 23.1 FDA Grants Fast Track Designation To Opct-001 For Treating Primary Photoreceptor Diseases
  • 23.2 Orphan Drug Designation Granted For Novel Retinitis Pigmentosa Gene Therapy
  • 23.3 Advancement Of Jcell Therapy To Phase 3 For Retinitis Pigmentosa
  • 23.4 Positive 12-Month Data From Phase 2 SKYLINE Trial Of Laru-Zova In XLRP Patients
  • 23.5 Advancing Gene Therapy for Retinitis Pigmentosa Treatment

24 Opportunities And Strategies

  • 24.1 Global Retinitis Pigmentosa Market In 2029 - Countries Offering Most New Opportunities
  • 24.2 Global Retinitis Pigmentosa Market In 2029 - Segments Offering Most New Opportunities
  • 24.3 Global Retinitis Pigmentosa Market In 2029 - Growth Strategies
    • 24.3.1 Market Trend Based Strategies
    • 24.3.2 Competitor Strategies

25 Retinitis Pigmentosa Market, Conclusions And Recommendations

  • 25.1 Conclusions
  • 25.2 Recommendations
    • 25.2.1 Product
    • 25.2.2 Place
    • 25.2.3 Price
    • 25.2.4 Promotion
    • 25.2.5 People

26 Appendix

  • 26.1 Geographies Covered
  • 26.2 Market Data Sources
  • 26.3 Research Methodology
  • 26.4 Currencies
  • 26.5 The Business Research Company
  • 26.6 Copyright and Disclaimer